New Drug Approved for Peripheral T-Cell Lymphoma (FREE)
By the Editors
The FDA has approved … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 7, 2014 Category: Primary Care Source Type: news
Beleodaq OK'd for Rare Form of NHL
WASHINGTON (MedPage Today) -- The FDA has approved the histone deacetylase inhibitor belinostat for treatment of peripheral T-cell lymphoma, an uncommon but aggressive form of non-Hodgkin's lymphoma (NHL). (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - July 3, 2014 Category: Hematology Source Type: news
FDA Approves Belinostat for Rare LymphomaFDA Approves Belinostat for Rare Lymphoma
The new drug is for peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin's lymphoma. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 3, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves Beleodaq to treat rare, aggressive form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. (Source: Food and Drug Administration)
Source: Food and Drug Administration - July 3, 2014 Category: American Health Source Type: news
Response to Alemtuzumab for Leukemic Cutaneous T-Cell LymphomaResponse to Alemtuzumab for Leukemic Cutaneous T-Cell Lymphoma
Patients with leukemic cutaneous T-cell lymphoma (CTCL) who have diffuse erythema are more likely to experience complete response to alemtuzumab therapy, according to results from a small series. Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 2, 2014 Category: Dermatology Tags: Hematology-Oncology News Source Type: news
Donor Lymphocyte Infusion Improves Survival in Relapsed LymphomaDonor Lymphocyte Infusion Improves Survival in Relapsed Lymphoma
Relapsed patients with peripheral T cell lymphoma after transplant show improved survival when treated with a donor lymphocyte infusion. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 9, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Novel Drug Shows Promise in T-Cell Lymphoma
DENVER (MedPage Today) -- An investigational drug, resiquimod, successfully healed cutaneous T-cell lymphoma lesions in a small peer-supported trial, researchers reported here. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 24, 2014 Category: Dermatology Source Type: news
Belinostat (PXD 101) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Belinostat (PXD 101) is a histone deacetylase (HDAC) inhibitor that is being investigated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - January 31, 2014 Category: Pharmaceuticals Source Type: news
Infinity reports positive Phase I results of lymphoma drug IPI-145
Infinity Pharmaceuticals has reported promising data from an ongoing Phase I trial of its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma 'IPI-145' in patients with relapsed/refractory T-cell lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - January 28, 2014 Category: Pharmaceuticals Source Type: news
Peripheral T-Cell Lymphoma: Time for a T-Cell–Centric Standard of Care
This is an exciting time in the treatment of PTCL, but with this opportunity comes responsibility. The challenge of how to optimize a plethora of promising new therapies for a small number of patients will drive therapeutic decision making for the foreseeable future. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news
Peripheral T-Cell Lymphoma: What’s the Role for Transplant?
The number of recently approved agents and those under investigation is promising. However, there are currently no recommendations regarding the optimal timing for use of these agents, a reflection of the lack of data in this area and the need for prospective studies. (Source: Cancer Network)
Source: Cancer Network - September 15, 2013 Category: Cancer & Oncology Source Type: news
First Proprietary Gel Product for Cutaneous Lymphoma First Proprietary Gel Product for Cutaneous Lymphoma
Although topical mechlorethamine (nitrogen mustard) has been used for decades in cutaneous T-cell lymphoma, only now is the product launched. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 27, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales & Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2013 Category: Pharmaceuticals Source Type: news
Molecular Profiling Helps Classify Peripheral T-Cell LymphomasMolecular Profiling Helps Classify Peripheral T-Cell Lymphomas
Up to 30% of peripheral T-cell lymphomas are misdiagnosed, but molecular profiling can help address that problem, according to a new paper. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Non-mycosis Fungoides Cutaneous T-cell LymphomasNon-mycosis Fungoides Cutaneous T-cell Lymphomas
Primary cutaneous CD30+ T-cell lymphoproliferative disorders and their differential diagnosis are highlighted in this report from the European Society for Hematopathology. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
